Noninvasix appoints David Giarracco as CEO

– USA, TX –  Noninvasix today announced the appointment of David Giarracco as its new CEO.

A veteran medical device executive with relevant critical care market experience, Giarracco will advance the commercialization of the only non-invasive patient monitoring device designed for earlier detection of life-threatening sepsis so it can be treated to improve patient outcomes.

“Dave is the right leader at the right time for Noninvasix,” said Dr. Tom Luby, Director of Texas Medical Center Innovation Venture Fund. “He has a deep understanding of launching new platform technologies that make a critical difference in patient safety and clinical outcomes while reducing overall healthcare costs.”

About David J. Giarracco

David Giarracco has extensive experience in the launch and global commercialization of novel patient-monitoring technologies in both hospital and home care settings. In leadership roles at Medtronic and Covidien, he successfully scaled organizations to exceed business plans by strategically developing markets, addressing commercial structure, and creating clinically focused solution-selling organizations. Giarracco combines this expertise with start-up experience as COO at SeaStar Medical and as a lead investor and board member at early-stage healthcare technology companies.

“Dave will play an essential role in helping refine our strategy and drive product development activity to realize our mission of better detecting and monitoring sepsis,” said Dr. Donald Prough, Rebecca Terry White Distinguished Professor and Chairman of the Department of Anesthesia at the University of Texas Medical Branch. “As a Noninvasix founder and practicing anesthesiologist, I am excited about our future and the opportunity to make a significant impact on this major healthcare challenge.”

“Prevention and control strategies for sepsis infections are urgently needed,” said David Giarracco. “We need new, non-invasive approaches for early diagnosis to reduce complications and save lives. Noninvasix technology promises to make a major difference in patient care, reduce healthcare costs and have wider applications beyond sepsis.”

Giarracco received his Bachelor of Science in Biomedical Engineering from Johns Hopkins University and his Master of Arts in Biomedical Engineering from The Johns Hopkins School of Medicine. He brings more than 25 years of medical technology experience as an engineer, commercial leader, and early-stage investor in innovative, category-defining technologies.

About Noninvasix

Noninvasix will be the first company to non-invasively monitor the ​severity of sepsis and septic shock, enabling clinicians to diagnose ​and monitor the response to treatment of tissue hypoxia in real-time. Its patented optoacoustic platform technology is the first solution to non-invasively and continuously measure central venous saturation. Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements, and evidence will expand the use and clinical impact of the technology into other indications and settings.

For more information:

About Texas Medical Center Venture Fund (TMCVF)

Noninvasix has been a part of the Texas Medical Center Venture Fund portfolio since 2018. TMCVF is the venture capital arm of the Texas Medical Center, the largest medical center in the world with a mission to serve the health, education, and research needs of Texas and the world. TMCVF are early-stage investors who take a long-term view to support the commercialization, launch, and growth of innovations in medical devices and digital health solutions.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.